Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide.
Cell culture, tissue chemistry and flow cytometry were used to determine whether antisense bcl-2 oligodeoxynucleotides enhanced the sensitivity of leukemia cells to arsenic trioxide. A combination of arsenic trioxide with antisense bcl-2 oligodeoxynucleotides inhibited cell growth, induced apoptosis and induced bcl-2 protein expression in K562 and NB4 leukemic cells more significantly than either arsenic trioxide or the oligodeoxynucleotides on their own (P<0.01). Thus, bcl-2 antisense oligodeoxynucleotides increase the sensitivity of leukemic cells to arsenic trioxide. Combined use of the two agents could be a novel and attractive strategy in leukemia treatment.
Zhang
Y
Y
Institute of Hematology, Medical College of Jinan University, Guangzhou 510632, China. tzyuan@jnu.edu.cn
Shen
W L
WL
D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D002455:Cell Division; D045744:Cell Line, Tumor; D004247:DNA / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D020014:K562 Cells; D007938:Leukemia / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D010087:Oxides / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D013997:Time Factors
D000970:Antineoplastic Agents; D001152:Arsenicals; D016376:Oligonucleotides, Antisense; D010087:Oxides; D019253:Proto-Oncogene Proteins c-bcl-2; D004247:DNA; D000077237:Arsenic Trioxide